Ute Hidding

Dr. Ute Hidding

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
CCChoe Chi-un
Choe Chi-un
UHUte Hidding
Ute Hidding
MSMiriam Schaper
Miriam Schaper
AGAlessandro Gulberti
Alessandro Gulberti
JKJohannes Köppen
Johannes Köppen
MPMonika Pötter-Nerger
Monika Pötter-Nerger
Objective To investigate the effect of directional current steering and short pulse stimulation in the ventral intermediate thalamic nucleus (VIM) on stimulation-induced side effects in patients with essential tremor. Methods We recruited 8 patients with essential tremor in a stable postoperative condition (>3 months after electrode implantation of deep brain stimulation [DBS] electrodes) with segmented contacts implanted in the VIM. Tremor severity on acute stimulation was assessed by the Fahn-Tolosa-Marin Tremor Rating Scale. Cerebellar impairment was evaluated with the International Cooperative Ataxia Rating Scale. Patients rated paresthesia intensity with a visual analog scale. Results In all patients, tremor was reduced to the same extent by VIM stimulation regardless of pulse width using energy dose–equivalent amplitudes. Short pulse stimulation diminished stimulation-induced ataxia of the upper extremities and paresthesia compared with conventional parameters. Directional steering with monopolar stimulation of single segments successfully suppressed tremor but also induced ataxia. No differences in adverse effects were found between single-segment stimulation conditions. Conclusion These proof-of-principle findings provide evidence that acute short pulse stimulation is superior to directional steering in the subthalamic area to decrease stimulation-induced side effects while preserving tremor suppression effects in patients with tremor. Classification of evidence This study provides Class IV evidence that for patients with tremor with thalamic DBS, acute short pulse stimulation reduces adverse effects, while directional steering does not provide a generalizable benefit regarding adverse effects.

1 April 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
CBCarsten Buhmann
Carsten Buhmann
TFTill Flügel
Till Flügel
MBMoritz Bihler
Moritz Bihler
CGChristian Gerloff
Christian Gerloff
ANAlmut Niessen
Almut Niessen
CPChristina Pflug
Christina Pflug

1 November 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
CGChristos Ganos
Christos Ganos
SZSimone Zittel
Simone Zittel
UHUte Hidding
Ute Hidding
CFClaudia Funke
Claudia Funke
SBSaskia Biskup
Saskia Biskup
KBKailash P. Bhatia
Kailash P. Bhatia

1 May 2019 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
UHUte Hidding
Ute Hidding
AGAlessandro Gulberti
Alessandro Gulberti
CPChristina Pflug
Christina Pflug
CCChoe Chi-un
Choe Chi-un
AHA. Horn
A. Horn
MPMonika Pötter-Nerger
Monika Pötter-Nerger

28 November 2023 in Journal of Neural Transmission
Verified
Journal Article
Open access
PDF file
UHUte Hidding
Ute Hidding
TMTina Mainka
Tina Mainka
CBCarsten Buhmann
Carsten Buhmann
The use of medical Cannabis has increased in recent years due to changing legal circumstances in many countries. Approval exists only for a few neurological conditions such as rare forms of epilepsy or spasticity in multiple sclerosis. Beyond that, however, medical Cannabis is used for a wide range of neurological conditions and symptoms. In Germany, in parallel with new legislation that has simplified the prescription of medical Cannabis, an accompanying survey has been implemented for which initial data are now available. In this context, our review provides an overview of the evidence for the therapeutic use of medical Cannabis in neurology, the potential benefits, and side effects.

1 January 2017 in Parkinson's Disease
Verified
Journal Article
Open access
PDF file
UHUte Hidding
Ute Hidding
AGAlessandro Gulberti
Alessandro Gulberti
AHA. Horn
A. Horn
CBCarsten Buhmann
Carsten Buhmann
WHW. Hamel
W. Hamel
MPMonika Pötter-Nerger
Monika Pötter-Nerger
The goal of the study was to compare the tolerability and the effects of conventional subthalamic nucleus (STN) and combined subthalamic nucleus and substantia nigra (STN+SNr) high-frequency stimulation in regard to neuropsychiatric symptoms in Parkinson’s disease patients. In this single center, randomized, double-blind, cross-over clinical trial, twelve patients with advanced Parkinson’s disease (1 female; age:61.3±7.3years; disease duration:12.3±5.4years; Hoehn and Yahr stage:2.2±0.39) were included. Apathy, fatigue, depression, and impulse control disorder were assessed using a comprehensive set of standardized rating scales and questionnaires such as the Lille Apathy Rating Scale (LARS), Modified Fatigue Impact Scale (MFIS), Becks Depression Inventory (BDI-I), Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease Rating Scale (QUIP-RS), and Parkinson’s Disease Questionnaire (PDQ-39). Three patients that were initially assigned to the STN+SNr stimulation mode withdrew from the study within the first week due to discomfort. Statistical comparison of data retrieved from patients who completed the study revealed no significant differences between both stimulation conditions in terms of mean scores of scales measuring apathy, fatigue, depression, impulse control disorder, and quality of life. Individual cases showed an improvement of apathy under combined STN+SNr stimulation. In general, combined STN+SNr stimulation seems to be safe in terms of neuropsychiatric side effects, although careful patient selection and monitoring in the short-term period after changing stimulation settings are recommended.